Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair

3 Jan 2020

Abstract excerpt

Abstract Purpose: Emergence of mismatch repair (MMR) deficiency is a frequent mechanism of acquired resistance to the alkylating chemotherapeutic temozolomide (TMZ) in gliomas. Poly(ADP-ribose) polymerase inhibitors (PARPi) have been shown to potentiate TMZ cytotoxicity in several cancer types, including gliomas. We tested whether PARP inhibition could re-sensitize MSH6-null MMR-deficient gliomas to TMZ, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic factors in colorectal cancer
Share to Glioma Diagnosis and Treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31900275
DOI: 10.1158/1078-0432.ccr-19-2000

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision RepairPMID 31900275Read ↗

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenograftsSemantic proximity Read ↗

PARP Inhibitor Counteracts Temozolomide Resistance in Glioblastoma MultiformeSemantic proximity Read ↗

Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomideSemantic proximity Read ↗

PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular HeterogeneitySemantic proximity Read ↗

MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.Semantic proximity Read ↗

Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.Semantic proximity Read ↗

MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapySemantic proximity Read ↗

Rad51 and BRCA2 - New Molecular Targets for Sensitizing Glioma Cells to Alkylating Anticancer DrugsSemantic proximity Read ↗

PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.Semantic proximity Read ↗

Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastomaSemantic proximity Read ↗

Trans-Lesion Synthesis and Mismatch Repair Pathway Crosstalk Defines Chemoresistance and Hypermutation Mechanisms in GlioblastomaSemantic proximity Read ↗

Olaparib: A Chemosensitizer for the Treatment of GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.